Julie F. Furberg works as a statistician in the pharmaceutical company Novo Nordisk, Denmark. Within Novo Nordisk, she is responsible for the clinical trials within chronic kidney disease, including the renal outcome trial FLOW which investigated the renal benefits of semaglutide. She has a PhD in Biostatistics from the University of Copenhagen. Her main statistical areas of interest are survival analysis, recurrent event analysis, multi-state models and causal inference.